Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine + dexamethasone + nystatin mouthwash for oral chronic graft-versus-host disease after HSCT
IRCT20140818018842N52Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jun 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of cyclosporine, dexamethasone and nystatin in chronic graft-versus-host disease (cGVHD), sponsored by Tehran University of Medical Sciences. Started Jun 2026; status: completed.
02
Drugs
cyclosporinedexamethasonenystatin
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on IRCT20140818018842N52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140818018842N52.